# Digital Endpoint Analysis Agent

**ID:** `biomedical.clinical.digital_endpoint`
**Version:** 1.0.0
**Status:** Beta
**Category:** Clinical AI / Digital Health

---

## Overview

The **Digital Endpoint Analysis Agent** extracts clinical endpoints from wearables, sensors, and continuous monitoring devices for clinical trials. Digital endpoints provide objective, continuous measurements that can increase trial sensitivity and capture real-world function.

---

## Key Capabilities

### 1. Data Sources

| Device | Measurements | Applications |
|--------|--------------|--------------|
| **Actigraphy** | Activity, sleep | Neurology, psychiatry |
| **Smartwatch** | HR, HRV, SpO2 | Cardiology, respiratory |
| **CGM** | Glucose | Diabetes |
| **Smartphone** | Gait, voice | Neurology, respiratory |
| **Implantables** | Cardiac rhythm | Cardiology |

### 2. Endpoint Types

| Category | Examples |
|----------|----------|
| **Motor function** | Gait speed, tremor, bradykinesia |
| **Sleep** | Total sleep time, efficiency, stages |
| **Cardiovascular** | HR variability, arrhythmia burden |
| **Respiratory** | Cough frequency, FEV1 proxy |
| **Cognitive** | Reaction time, processing speed |

### 3. Analysis Methods

- **Signal processing:** Filtering, feature extraction
- **Machine learning:** Activity classification
- **Statistical modeling:** Longitudinal analysis
- **Digital biomarker validation:** Reliability, sensitivity

---

## Usage

### Example Prompt

```text
Analyze digital endpoint data from a Parkinson's disease trial.

Data:
- Continuous accelerometer (wrist-worn) for 12 weeks
- Smartphone tapping test daily
- 50 patients on active drug, 50 on placebo

Extract digital biomarkers of motor function and compare treatment effect.
```

### Expected Output

```
## Digital Endpoint Analysis: Parkinson's Trial

### Data Quality
| Metric | Value | Acceptable |
|--------|-------|------------|
| Wear time compliance | 89% | >80% ✓ |
| Missing days | 8% | <15% ✓ |
| Tapping compliance | 92% | >85% ✓ |

### Digital Biomarkers Extracted

#### Accelerometer-based
| Biomarker | Description | Units |
|-----------|-------------|-------|
| **Bradykinesia score** | Movement amplitude | AU |
| **Tremor power** | 4-6 Hz spectral power | g²/Hz |
| **Gait speed** | Walking velocity | m/s |
| **Turn duration** | Time to complete 180° turn | seconds |

#### Smartphone Tapping
| Biomarker | Description | Units |
|-----------|-------------|-------|
| **Tap rate** | Taps per 10 seconds | count |
| **Tap variability** | CV of inter-tap interval | % |
| **Fatigue slope** | Decline over 30 seconds | taps/s² |

### Treatment Effect Analysis

| Endpoint | Placebo Δ | Active Δ | Difference | p-value |
|----------|-----------|----------|------------|---------|
| **Bradykinesia** | -0.05 | -0.28 | 0.23 | 0.008 |
| **Tremor power** | +0.02 | -0.18 | 0.20 | 0.012 |
| **Gait speed** | +0.01 m/s | +0.08 m/s | 0.07 | 0.023 |
| **Tap rate** | +0.2 | +2.1 | 1.9 | 0.004 |

### Sensitivity Comparison

| Endpoint Type | Effect Size | Sensitivity |
|---------------|-------------|-------------|
| MDS-UPDRS (clinical) | 0.35 | Reference |
| Digital (bradykinesia) | 0.52 | **+49%** |
| Digital (composite) | 0.61 | **+74%** |

### Conclusion
Digital endpoints detected treatment effect with higher sensitivity
than traditional clinical scales, supporting smaller sample sizes
in future trials.
```

---

## References

- **Dorsey et al. (2017):** "The use of smartphones for health research." *Academic Medicine*
- **FDA Digital Health Center of Excellence:** Guidance on digital endpoints

---

## Author

**MD BABU MIA**
*Artificial Intelligence Group*
*Icahn School of Medicine at Mount Sinai*
md.babu.mia@mssm.edu
